Clinical Research
Summaries of peer-reviewed trials exploring cannabis in pain, sleep, and neurology.
Clinical Research · page 2
- CBD Market
Clinical Evidence vs. Food Law: Europe’s CBD Dilemma
The CBD sector has had a turbulent few weeks on both sides of the Channel, with the European Food Safety Authority (EFSA) terminating four novel food applications, just days after announcing incredibly restrictive new safety limits.
- Clinical Research
Can the Company That Built Australia’s Pastilles Market Do It Again in the UK?
Australia’s booming medical cannabis market, now the largest outside of North America, has seen a dramatic shift in consumer preference over the last two years.
- Clinical Research
Latest Studies Map Cannabis Efficacy Across Pain, Migraine, and Autism Applications
Welcome to Business of Cannabis’ new research digest, unpacking the latest clinical evidence shaping cannabis therapeutics.
- Clinical Research
SOMAÍ and Universidade Lusófona Publish Peer-Reviewed Study Validating Full-Spectrum Oil Consistency
SOMAÍ, a leading EU-GMP-certified vertically integrated Multi-Country Operator (MCO) specialising in cannabinoid-based medicines, together with Universidade Lusófona, has published their 4th peer-reviewed study titled “Genotype and chemotype insights of high-THC medicinal Cannabis sativa L.: the role of SSR markers in the identification of cultivars” in the Journal of Cannabis Research.
- Clinical Research
Industry Leaders React to Historic Cannabis Rescheduling
President Donald Trump’s executive order directing federal agencies to move cannabis from Schedule I to Schedule III of the Controlled Substances Act represents the most significant shift in US drug policy in over half a century.
- Clinical Research
Cannabis Rescheduling is Here: Trump Signs Executive Order to Move Cannabis to Schedule III
After two years of speculation, rumours, stock swings, broken promises, and political theatre, President Donald Trump officially signed an executive order (EO) to push cannabis rescheduling through on Thursday (December 18).
- Clinical Research
Veterans and Medical Cannabis: Can Private Clinics Fill NHS Treatment Gaps?
The UK’s health service is fighting to keep its head above water, yet with a record-breaking winter flu pandemic sweeping the nation, and a looming industrial action set to see thousands of resident doctors walk out later this week, the water level is rising rapidly.
- Clinical Research
‘Blockbuster’ Cannabis Drug To Be Released in 2026
Findings from the successful trials of a new, multi-compound, cannabis medicine look set to deliver a major breakthrough for the world’s half-a-billion chronic low back pain (CLB) sufferers.
- Clinical Research
Ananda Exits Landmark NHS-Funded Epilepsy Trial and Public Markets
Ananda Pharma, one of the UK’s leading clinical-stage pharmaceutical cannabis companies, has announced a string of strategic pivots, including stepping away from a flagship UK clinical trial into epilepsy.
- Clinical Research
Cannabis Health Symposium 2025 – Key Takeaways Part 2
The afternoon sessions at Tuesday’s inaugural Cannabis Health Symposium 2025 moved beyond the fundamentals of cannabis medicine and its potential, to the practical realities of prescribing this relatively new medicine in the UK.
- Clinical Research
Cannabis Health Symposium 2025 – Key Takeaways Part 1
On Tuesday, November 25, nearly 200 healthcare professionals, patient advocates, cannabis educators, and industry leaders converged on London’s Conway Hall for the inaugural Cannabis Health Symposium.
- Clinical Research
EU ‘Intoxicating Hemp’ Review Highlights Major Knowledge Gaps Behind Blanket Bans
Last week, the US government voted to impose a blanket ban on all so-called ‘intoxicating hemp’ substances, ending what has been a contentious and long-running battle to regulate the recent emergence of THC substitutes.
